1-14 of 14
Timothy J. Purwin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 6942: Single cell resolution of intrapatient drug resistance mechanisms in metastatic melanoma

Haley P. Wilson, Glenn L. Mersky, Jelan I. Haj, Jessica Teh, Phil F. Cheng, Signe Caksa, Casey D. Stefanski, Vivian Chua, Claudia Capparelli, Mitch P. Levesque, Reinhard Dummer, Timothy J. Purwin, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6942.
https://doi.org/10.1158/1538-7445.AM2024-6942
Published: 22 March 2024
View article titled, Abstract 6942: Single cell resolution of intrapatient drug resistance mechanisms in metastatic melanoma
Journal Articles

Abstract 1256: Transglutaminase-2 is elevated in the invasive cell state and modulates the tumor immune microenvironment in cutaneous melanoma

Signe Caksa, Nicole A. Wilski, Erica L. Kitterman, McKenna Q. Glasheen, Jacob S. Heilizer, Timothy J. Purwin, Claudia Capparelli, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1256.
https://doi.org/10.1158/1538-7445.AM2023-1256
Published: 04 April 2023
View article titled, Abstract 1256: Transglutaminase-2 is elevated in the invasive cell state and modulates the tumor immune microenvironment in cutaneous melanoma
Journal Articles

Abstract 1301: Evolution of heterogenous BRAFi/MEKi+CDK4/6i resistance mechanisms and targeting site-specific resistant populations in metastatic cutaneous melanoma

Haley P. Wilson, Timothy J. Purwin, Claudia Capparelli, Phil F. Cheng, Mitch P. Levesque, Reinhard Dummer, Jessica Teh, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1301.
https://doi.org/10.1158/1538-7445.AM2023-1301
Published: 04 April 2023
View article titled, Abstract 1301: Evolution of heterogenous BRAFi/MEKi+CDK4/6i resistance mechanisms and targeting site-specific resistant populations in metastatic cutaneous melanoma
Journal Articles

Abstract A005: The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma

Manoela Tiago, Timothy J. Purwin, Mitchell E. Fane, Yash Chhabra, Jessica L. F. Teh, Rama Kadamb, Weijia Cai, Inna Chervoneva, Sheera Rosenbaum, Vivian Chua, Nir Hacohen, Michael A. Davies, Jessie Villanieva, Ashani T. Weeraratna, Claudia Capparelli, Julio A. Aguirre-Ghiso, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2023) 83 (2_Supplement_1): A005.
https://doi.org/10.1158/1538-7445.AGCA22-A005
Published: 15 January 2023
View article titled, Abstract A005: The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma
Journal Articles

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma

Weijia Cai, Mai Q. Nguyen, Nicole A. Wilski, Timothy J. Purwin, Mégane Vernon, Manoela Tiago, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2022) 82 (14): 2625–2639.
https://doi.org/10.1158/0008-5472.CAN-21-3217
Published: 18 July 2022
View article titled, A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <em>NRAS</em> Mutant Melanoma
Open the PDF for A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <em>NRAS</em> Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract 860: Identifying mechanisms associated with slow proliferation of BAP1 mutant uveal melanoma cells

Vivian Chua, Usman Baqai, Timothy J. Purwin, Angela Jeon, Anna Han, Andrew Aplin
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 860.
https://doi.org/10.1158/1538-7445.AM2022-860
Published: 15 June 2022
View article titled, Abstract 860: Identifying mechanisms associated with slow proliferation of BAP1 mutant uveal melanoma cells
Journal Articles

Abstract 40: Targeting SOX10-deficient cells to reduce resistance to targeted therapy in melanoma

Claudia Capparelli, Timothy J. Purwin, Manoela Tiago, Nicole Wilski, Danielle Pomante, McKenna Glasheen, Sheera Rosenbaum, Mai Q. Nguyen, Weijia Cai, Richard Zheng, Gaurav Kumar, Inna Chervoneva, Ayako Shimada, Adam E. Snook, Paolo Fortina, Xiaowei Xu, Kim Hookim, Edna Cukierman, Michael A. Davies, Meenhard Herlyn, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 40.
https://doi.org/10.1158/1538-7445.AM2021-40
Published: 01 July 2021
View article titled, Abstract 40: Targeting SOX10-deficient cells to reduce resistance to targeted therapy in melanoma
Journal Articles

Roles of the BAP1 Tumor Suppressor in Cell Metabolism

Anna Han, Timothy J. Purwin, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2021) 81 (11): 2807–2814.
https://doi.org/10.1158/0008-5472.CAN-20-3430
Published: 01 June 2021
View article titled, Roles of the BAP1 Tumor Suppressor in Cell Metabolism
Open the PDF for Roles of the BAP1 Tumor Suppressor in Cell Metabolism in another window
Journal Articles

Abstract A22: Effects of CDK4/6/MAPK targeting combinations on melanoma and the tumor immune microenvironment

Jessica L.F. Teh, Phil F. Cheng, Dan E. Erkes, Timothy J. Purwin, Conroy Field, Connor Hollingworth, Julio Aguirre-Ghiso, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2020) 80 (19_Supplement): A22.
https://doi.org/10.1158/1538-7445.MEL2019-A22
Published: 02 October 2020
View article titled, Abstract A22: Effects of CDK4/6/MAPK targeting combinations on melanoma and the tumor immune microenvironment
Journal Articles

Abstract 2986: NR2F1 underlies persistence of residual disease in melanoma

Manoela Tiago, Jessica L. Teh, Timothy J. Purwin, Weijia Cai, Connor Hollingworth, Melisa Lopez-Anton, Julio A. Aguirre-Ghiso, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 2986.
https://doi.org/10.1158/1538-7445.AM2020-2986
Published: 15 August 2020
View article titled, Abstract 2986: NR2F1 underlies persistence of residual disease in melanoma
Journal Articles

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma

Claudia Capparelli, Timothy J. Purwin, Shea A. Heilman, Inna Chervoneva, Peter A. McCue, Adam C. Berger, Michael A. Davies, Jeffrey E. Gershenwald, Clemens Krepler, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2018) 78 (19): 5680–5693.
https://doi.org/10.1158/0008-5472.CAN-18-1001
Published: 01 October 2018
View article titled, ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
Open the PDF for ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract 2304: In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms

Jessica Teh, Phil F. Cheng, Timothy J. Purwin, Neda Nikbakht, Prem Patel, Inna Chervoneva, Ines Keibler, HooKim Kim, Michael A. Davies, Lawrence N. Kwong, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2304.
https://doi.org/10.1158/1538-7445.AM2018-2304
Published: 01 July 2018
View article titled, Abstract 2304: In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms
Journal Articles

Abstract 105: CADM1 is a TWIST1-regulated suppressor of melanoma invasion and survival

Edward J. Hartsough, Michele B. Weiss, Shea A. Heilman, Timothy J. Purwin, Curtis H. Kugel, Sheera R. Rosenbaum, Dan A. Erkes, Manoela Tiago, Inna Chervoneva, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 105.
https://doi.org/10.1158/1538-7445.AM2018-105
Published: 01 July 2018
View article titled, Abstract 105: CADM1 is a TWIST1-regulated suppressor of melanoma invasion and survival
Journal Articles

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma

Jessica L.F. Teh, Timothy J. Purwin, Evan J. Greenawalt, Inna Chervoneva, Allison Goldberg, Michael A. Davies, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2016) 76 (18): 5455–5466.
https://doi.org/10.1158/0008-5472.CAN-15-3384
Published: 15 September 2016
View article titled, An <em>In Vivo</em> Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma
Open the PDF for An <em>In Vivo</em> Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma in another window
Includes: Supplementary data